eniferBio Oy
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
eniferBio Oy - overview
Established
2020
Location
Espoo, Uusimaa, Finland
Primary Industry
Biotechnology
About
Based in Finland, eniferBio Oy specializes in developing innovative mycoprotein solutions, focusing on sustainable protein alternatives for various industries, including aquaculture and pet food. Founded in 2020 and headquartered in Espoo, Finland, eniferBio Oy focuses on mycoprotein development for sustainable food sources. The company was established by a team of founders including Anssi Rantasalo, Joosu Kuivanen, Simo Ellilä, and Ville Pihlajaniemi. The latest funding round, a Series B, raised EUR 15.
000 mn, led by Taaleri Bioindustry, with a total amount raised of EUR 15. 000 mn. The company has completed six deals, with the most recent on May 23, 2024. EniferBio specializes in mycoprotein solutions, with its flagship product PEKILO®, a fungi-based protein used in aquafeed, pet food, and other food applications.
PEKILO®Aqua and PEKILO®Pet are tailored for aquaculture and pet food, respectively, meeting the demand for sustainable protein sources. The products are marketed in North America and Europe to food manufacturers and pet food producers. For the year 2024, eniferBio reported no revenue, with an EBITDA loss of EUR 3,090,965. 60.
EniferBio plans to utilize the recent funding of EUR 9 million, raised in May 2024, to support ongoing project development. The company aims to expand its product offerings and explore new markets, focusing on strengthening its presence in Europe and North America by 2025.
Current Investors
Tesi, Aqua-Spark, Voima Ventures
Primary Industry
Biotechnology
Sub Industries
Health Foods & Nutritional Supplements, Biopharmaceuticals
Website
www.enifer.com
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
eniferBio Oy - timeline of key events
eniferBio Oy - financials
| Fiscal Year Ended | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|
| Revenue (USD) | 6,531 | 59,500 | - | - | - |
| % Revenue Growth (YoY) | - | 811.0% | - | - | - |
| EBITDA (USD) | (53,306.5) | (209,191.4) | - | - | - |
| Operating Income (USD) | (66,138.1) | (373,400.7) | - | - | - |
| Operating Margin | (1012.7%) | (627.6%) | - | - | - |
| % EBITDA Margin | (816.2%) | (351.6%) | - | - | - |
| NET Income (USD) | (66,137.6) | (375,293.1) | - | - | - |
| % Net Margin | (1012.7%) | (630.7%) | - | - | - |
eniferBio Oy - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.